Nanoerythropoietin Is 10-Times More Effective Than Regular Erythropoietin in Neuroprotection in a Neonatal Rat Model of Hypoxia and Ischemia
Nanoerythropoietin Is 10-Times More Effective Than Regular Erythropoietin in Neuroprotection in a Neonatal Rat Model of Hypoxia and Ischemia
复制标题
DOI：
10.1161/strokeaha.111.637090
复制
发表时间：
2012-03-01
期刊：
影响因子：
8.3
通讯作者：
Zhang, John H.
中科院分区：
文献类型：
--
作者：
Chen, Han;Spagnoli, Frederic;Zhang, John H.
背景和目的：促红细胞生成素（EPO）已被证明在卒中中具有显著的神经保护作用。我们确定纳米药物形式的人类重组EPO（PLGA-EPO纳米颗粒[PLGA-EPO-NP]）与人重组EPO（r-EPO）相比可以在较低剂量下增强神经保护作用。方法-使用建立的单侧缺血性中风的新生大鼠模型来比较每天腹膜内注射给予的r-EPO、PLGA-EPO-NP和磷酸盐缓冲盐水，结果PLGA-EPO-NP组与相同浓度的r-EPO组相比，伤后72小时梗死体积明显减小。与对照组相比，300 U/kg PLGA-EPO-NP显著降低了功能缺陷，与r-EPO. Conclusions相比，PLGA-EPO-NP在显著降低的剂量下对脑缺血后的缺陷具有神经保护作用和益处。（中风。2012;43：884-887）。
Background and Purpose-Erythropoietin (EPO) has been demonstrated to possess significant neuroprotective effects in stroke. We determined if the nano-drug form of human recombinant EPO (PLGA-EPO nanoparticles [PLGA-EPO-NP]) can enhance neuroprotection at lower dosages versus human recombinant EPO (r-EPO).Methods-Established neonatal rat model of unilateral ischemic stroke was used to compare r-EPO, PLGA-EPO-NP and phosphate-buffered saline, given by daily intraperitoneal injections, followed by infarction volume and Rotarod Performance Test assessment.Results-PLGA-EPO-NP significantly reduced infarction volumes 72 hours after injury compared with the same concentrations of r-EPO. Functional deficits were significantly reduced by 300 U/kg PLGA-EPO-NP versus controls, with deficit attenuation apparent at significantly lower dosages of PLGA-EPO-NP versus r-EPO.Conclusions-PLGA-EPO-NP is neuroprotective and beneficial against deficits after brain ischemia, at significantly reduced dosages versus r-EPO. (Stroke. 2012;43:884-887.)